Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.49 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29368677 | 0.80 | NPC1 (0.60) | NPC1RAB9AGFERKDM1ARCOR1 | |
| SCHEMBL4954697 | 0.80 | NPC1 (0.59) | NPC1RAB9AGFERKDM1ARCOR1 | |
| SCHEMBL7589089 | 0.79 | KDM1A (0.61) | NPC1RAB9AGFERKDM1ARCOR1 | |
| SCHEMBL22822554 | 0.79 | RAB9A (0.58) | NPC1RAB9AGFERKDM1ARCOR1 | |
| SCHEMBL6037540 | 0.79 | NPC1 (0.58) | NPC1RAB9AGFERKDM1ARCOR1 | |
| SCHEMBL16692690 | 0.79 | NPC1 (0.58) | NPC1RAB9AGFERKDM1ARCOR1 | |
| SCHEMBL6037543 | 0.79 | KDM4E (0.60) | NPC1RAB9AGFERKDM1ARCOR1 | |
| Hydrochloric Acid SCHEMBL31228757 | 0.78 | KDM1A (0.60) | NPC1RAB9AGFERKDM1ARCOR1 | |
| SCHEMBL16692713 | 0.77 | NPC1 (0.66) | NPC1RAB9ATYK2MEN1KMT2A | |
| SCHEMBL4525537 | 0.74 | SCN9A (0.57) | NPC1RAB9AGFERKDM1ARCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11629125-B2 | Elimination of hepatitis b virus with antiviral agents | EMORY UNIVERSITY (US) | 2023-04-18 | — | — | US | disclosed |
| US-9682931-B2 | Aryloyl(oxy or amino)pentafluorosulfanylbenzene compound, pharmaceutically acceptable salt thereof, and prodrugs thereof | UBE INDUSTRIES, LTD. (JP) | 2017-06-20 | — | — | US | disclosed |
| US-9682931-B2 | Aryloyl(oxy or amino)pentafluorosulfanylbenzene compound, pharmaceutically acceptable salt thereof, and prodrugs thereof | UBE INDUSTRIES, LTD. (JP) | 2017-06-20 | — | — | US | disclosed |
| EP-3064489-A1 | ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF | Ube Industries, Ltd. (JP) | 2016-09-07 | — | — | EP | disclosed |
| EP-3064489-A1 | ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF | Ube Industries, Ltd. (JP) | 2016-09-07 | — | — | EP | disclosed |
| US-20160244407-A1 | ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF | UBE INDUSTRIES, LTD. (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20160244407-A1 | ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF | UBE INDUSTRIES, LTD. (JP) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244407-A1 | ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF | SLCO1B1, SLCO2B1, SLCO1B3 | NPC1 1429/4885RAB9A 793/4885GFER 480/4885 |
| US-11629125-B2 | Elimination of hepatitis b virus with antiviral agents | HAVCR2, SLC10A1, ABCB11 | NPC1 32/4885RAB9A 1252/4885GFER 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.